Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.
Kosloski MP, Guttman-Yassky E, Cork MJ, Worm M, Nahm DH, Zhu X, Ruddy MK, Harel S, Kamal MA, Goulaouic H, Xu CR, Avetisova E, Davis JD, Nivens MC, Shabbir A, Radin A. Kosloski MP, et al. Clin Transl Sci. 2024 Aug;17(8):e13874. doi: 10.1111/cts.13874. Clin Transl Sci. 2024. PMID: 39077906 Free PMC article. Clinical Trial.
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Kamal MA, Kosloski MP, Lai CH, Partridge MA, Rajadhyaksha M, Kanamaluru V, Bansal A, Shabbir A, Shumel B, Ardeleanu M, Richards SM, Yan H, Xu CR, Rodríguez-Marco A, Xiao J, Khokhar FA, Gherardi G, Babilonia E, Maloney J, Mortensen E, Akinlade B, Braunstein N, Stahl N, Torri A, Davis JD, DiCioccio AT. Kamal MA, et al. Among authors: kosloski mp. Front Immunol. 2024 Nov 11;15:1466372. doi: 10.3389/fimmu.2024.1466372. eCollection 2024. Front Immunol. 2024. PMID: 39588375 Free PMC article. Clinical Trial.
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.
Rabe KF, Martinez FJ, Bhatt SP, Kawayama T, Cosio BG, Mroz RM, Boomsma MM, Goulaouic H, Nivens MC, Djandji M, Soler X, Liu Y, Kosloski MP, Xu CR, Amin N, Staudinger H, Lederer DJ, Abdulai RM. Rabe KF, et al. Among authors: kosloski mp. ERJ Open Res. 2024 Sep 23;10(5):00718-2023. doi: 10.1183/23120541.00718-2023. eCollection 2024 Sep. ERJ Open Res. 2024. PMID: 39319046 Free PMC article.
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, Hirano I, Liu R, Laws E, Mortensen E, Martincova R, Shabbir A, McCann E, Kamal MA, Kosloski MP, Hamilton JD, Samuely C, Lim WK, Wipperman MF, Farrell A, Patel N, Yancopoulos GD, Glotfelty L, Maloney J. Chehade M, et al. Among authors: kosloski mp. N Engl J Med. 2024 Jun 27;390(24):2239-2251. doi: 10.1056/NEJMoa2312282. N Engl J Med. 2024. PMID: 38924731 Clinical Trial.
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development.
Davis JD, Bravo Padros M, Conrado DJ, Ganguly S, Guan X, Hassan HE, Hazra A, Irvin SC, Jayachandran P, Kosloski MP, Lin KJ, Mukherjee K, Paccaly A, Papachristos A, Partridge MA, Prabhu S, Visich J, Welf ES, Xu X, Zhao A, Zhu M. Davis JD, et al. Among authors: kosloski mp. Clin Pharmacol Ther. 2024 Mar;115(3):422-439. doi: 10.1002/cpt.3150. Epub 2024 Jan 10. Clin Pharmacol Ther. 2024. PMID: 38093583 Review.
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis.
Briggs E, Kamal MA, Kosloski MP, Linsmeier I, Jusko N, Dolphin N, Chittenden J, Simpson EL, Paller AS, Siegfried EC, Shumel B, Levit NA, Bansal A, Davis JD, Chapel S, Smith DE, Huniti N. Briggs E, et al. Among authors: kosloski mp. Pharm Res. 2023 Nov;40(11):2653-2666. doi: 10.1007/s11095-023-03616-8. Epub 2023 Dec 11. Pharm Res. 2023. PMID: 38082089 Free PMC article.
44 results